[Cinacalcet hydrochloride and phosphate metabolism]

Area of Science:

• Nephrology
• Pharmacology
• Endocrinology

Background:

• Cinacalcet hydrochloride (cinacalcet) is known to inhibit blood phosphorus (P) levels.
• This effect is primarily observed in patients undergoing dialysis.

Purpose of the Study:

• To investigate the differential effects of cinacalcet on phosphorus levels in dialysis versus pre-dialysis chronic kidney disease (CKD) patients.
• To validate the trade-off hypothesis regarding cinacalcet's impact on mineral metabolism.

Main Methods:

• Comparative analysis of cinacalcet's effects in human patients (dialysis and pre-dialysis CKD) and animal models (normal and CKD rats).
• Evaluation of parathyroid hormone (PTH) levels, urinary phosphorus excretion, and phosphorus mobilization from bone.

Main Results:

• In dialysis patients, cinacalcet lowers blood P by decreasing PTH secretion, reducing bone P mobilization.
• In pre-dialysis CKD patients and rats, cinacalcet increases blood P levels and decreases urinary P excretion.
• The drug's P-lowering effect in dialysis patients may inhibit vascular calcification.

Conclusions:

• Cinacalcet exhibits distinct effects on phosphorus metabolism depending on CKD stage.
• The P-lowering effect in dialysis patients is linked to reduced PTH and bone P release, potentially benefiting vascular health.
• Further research is needed to determine if cinacalcet's benefits in dialysis patients reduce mortality risk.